Page last updated: 2024-12-08

colchiceine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID234105
CHEMBL ID142588
CHEBI ID183909
SCHEMBL ID177858
MeSH IDM0060189

Synonyms (82)

Synonym
nsc-123396
acetamide,6,7,9-tetrahydro-10-hydroxy-1,2,3-trimethoxy-9-oxobenzo[a]heptalen-7-yl)-, (s)-
colchiceine
477-27-0
n-acetyl trimethylcolchicinic acid
7-acetamido-10-hydroxy-1,3-trimethoxy-6,7-dihydrobenzo[a]heptalen-9(5h)-one
o10-demethylcolchicine
nsc123396
wln: l b677 mv&t&j co1 do1 eo1 jmv1 nq
benzo[a]heptalen-9(5h)-one,7-dihydro-10-hydroxy-1,2,3-trimethoxy-
NSC33411 ,
nsc-33411
DIVK1C_006923
NCI60_002925
SDCCGMLS-0066903.P001
BSPBIO_002741
nsc 123396
benzo(a)heptalen-10(5h)-one, 7-acetamido-6,7-dihydro-9-hydroxy-1,2,3-trimethoxy-
o-demethylcolchicine
brn 2824078
benzo(a)heptalen-9(5h)-one, 7-acetamido-6,7-dihydro-10-hydroxy-1,2,3-trimethoxy-
nsc 33411
acetamide, n-(5,6,7,9-tetrahydro-10-hydroxy-1,2,3-trimethoxy-9-oxobenzo(a)heptalen-7-yl)-, (s)-
7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo(a)heptalen-9(5h)-one
colchiceine (van)
o(sup 10)-demethylcolchicine
einecs 207-512-5
SPECTRUM_000357
NCGC00017342-01
tnp00282
SPECTRUM5_001013
NCGC00178495-01
NCGC00142518-01
KBIO1_001867
KBIO2_000837
KBIO2_005973
KBIOSS_000837
KBIO2_003405
KBIO3_002241
KBIOGR_001044
SPECPLUS_000827
SPECTRUM3_001161
SPECTRUM4_000582
SPECTRUM2_000296
SPBIO_000232
SPECTRUM1800067
CHEMBL142588 ,
smr001397084
MLS002472977
bdbm50157477
n-((s)-10-hydroxy-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydro-benzo[a]heptalen-7-yl)-acetamide
CHEBI:183909
n-[(7s)-10-hydroxy-1,2,3-trimethoxy-9-oxo-6,7-dihydro-5h-benzo[a]heptalen-7-yl]acetamide
AKOS004110611
n-((7s)-10-hydroxy-1,2,3-trimethoxy-9-oxo-5,6,7-trihydrobenzo[d]heptalen-7-yl) acetamide
unii-hj30158l57
4-14-00-00943 (beilstein handbook reference)
hj30158l57 ,
HMS2205M17
CCG-39854
NCGC00017342-03
NCGC00017342-02
n-((7s)-5,6,7,9-tetrahydro-10-hydroxy-1,2,3-trimethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide
colchiceine [mi]
colchicine impurity f [ep impurity]
acetamide, n-((7s)-5,6,7,9-tetrahydro-10-hydroxy-1,2,3-trimethoxy-9-oxobenzo(a)heptalen-7-yl)-
2sj ,
n-[(7s)-10-hydroxy-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide
SCHEMBL177858
n-[(7s)-10-hydroxy-1,2,3-trimethoxy-9-oxo-6,7-dihydro-5h-benzo[d]heptalen-7-yl]acetamide
MS-2274
colchicein
gtpl7525
acetamide, n-(5,6,7,9-tetrahydro-10-hydroxy-1,2,3-trimethoxy-9-oxobenzo[a]heptalen-7-yl)-, (s)-
7-acetamido-10-hydroxy-1,2,3-trimethoxy-6,7-dihydrobenzo(a)heptalen-9(5h)-one, (s)-
n-(10-hydroxy-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide-, (s)-
n-{(7s)-10-hydroxy-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl}acetamide
coichiceine
Q27089242
DTXSID60878565 ,
(s)-n-(10-hydroxy-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide
dtxcid101016609

Research Excerpts

Overview

Colchiceine is a colchicine-metabolite. It has been reported to inhibit axonal transport although not binding to brain tubulin.

ExcerptReferenceRelevance
"Colchiceine is a colchicine-metabolite which has been reported to inhibit axonal transport although not binding to brain tubulin. "( Comparison of the in vitro effects of colchicine and its derivative colchiceine on chondrocyte morphology and function.
Friberg, U; Madsen, K; Moskalewski, S; Thyberg, J, 1979
)
1.94

Toxicity

ExcerptReferenceRelevance
" EIN was less toxic than COL based on both parameters within the concentration range 1-100 microM."( Comparative effect of colchicine and colchiceine on cytotoxicity and CYP gene expression in primary human hepatocytes.
Dvorak, Z; Maurel, P; Modriansky, M; Pichard-Garcia, L; Ulrichova, J, 2002
)
0.59

Dosage Studied

ExcerptRelevanceReference
" We have already reported that dosing of the test compound after partial hepatectomy (PH) is essential to detect genotoxicity of numerical chromosome aberration inducers in mice [Mutat."( Structural and numerical chromosome aberration inducers in liver micronucleus test in rats with partial hepatectomy.
Hattori, C; Itoh, S; Nagata, M; Sanbuissho, A, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cyclic ketone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (23)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency11.22020.177814.390939.8107AID2147
glp-1 receptor, partialHomo sapiens (human)Potency6.30960.01846.806014.1254AID624417
ATAD5 protein, partialHomo sapiens (human)Potency29.08100.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency79.43280.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency5.15730.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency35.48130.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency6.30960.707912.194339.8107AID720542
IDH1Homo sapiens (human)Potency6.51310.005210.865235.4813AID686970
cytochrome P450 2C9 precursorHomo sapiens (human)Potency15.84890.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.12540.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency8.91250.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency8.91250.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency8.91250.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency17.35820.004611.374133.4983AID624296; AID624297
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency13.72280.058010.694926.6086AID588379; AID602310
lethal factor (plasmid)Bacillus anthracis str. A2012Potency12.58930.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tubulin beta-1 chainHomo sapiens (human)IC50 (µMol)2.90000.00051.987010.0000AID241148
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aryl hydrocarbon receptor nuclear translocatorHomo sapiens (human)AC5040.77000.190023.3694115.5100AID651703
transforming acidic coiled-coil-containing protein 3Homo sapiens (human)AC5040.77000.190024.2333115.5100AID651703
HSP40, subfamily A [Plasmodium falciparum 3D7]Plasmodium falciparum 3D7AbsAC1000_uM1.86900.12904.116911.3160AID540271
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
platelet formationTubulin beta-1 chainHomo sapiens (human)
thyroid gland developmentTubulin beta-1 chainHomo sapiens (human)
microtubule polymerizationTubulin beta-1 chainHomo sapiens (human)
spindle assemblyTubulin beta-1 chainHomo sapiens (human)
thyroid hormone transportTubulin beta-1 chainHomo sapiens (human)
platelet aggregationTubulin beta-1 chainHomo sapiens (human)
mitotic cell cycleTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeleton organizationTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
GTPase activityTubulin beta-1 chainHomo sapiens (human)
metal ion bindingTubulin beta-1 chainHomo sapiens (human)
structural constituent of cytoskeletonTubulin beta-1 chainHomo sapiens (human)
GTP bindingTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmTubulin beta-1 chainHomo sapiens (human)
microtubule cytoskeletonTubulin beta-1 chainHomo sapiens (human)
intercellular bridgeTubulin beta-1 chainHomo sapiens (human)
extracellular exosomeTubulin beta-1 chainHomo sapiens (human)
mitotic spindleTubulin beta-1 chainHomo sapiens (human)
microtubuleTubulin beta-1 chainHomo sapiens (human)
cytoplasmTubulin beta-1 chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID252042In vitro cytotoxic activity against multi drug resistant KB subclone expressing P-glycoprotein (KB-V)2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Antitumor agents. Part 236: Synthesis of water-soluble colchicine derivatives.
AID253355In vitro cytotoxic activity against human lung carcinoma (A549) tumor cell line2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Antitumor agents. Part 236: Synthesis of water-soluble colchicine derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID253356In vitro cytotoxic activity against human ovarian carcinoma (1A9) tumor cell line2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Antitumor agents. Part 236: Synthesis of water-soluble colchicine derivatives.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID241148Inhibitory concentration against tubulin assembly2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Antitumor agents. Part 236: Synthesis of water-soluble colchicine derivatives.
AID253360In vitro cytotoxic activity against human epidermoid carcinoma of the nasopharynx (KB) tumor cell line2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
Antitumor agents. Part 236: Synthesis of water-soluble colchicine derivatives.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345665Human bromodomain containing 4 (Bromodomain kinase (BRDK) family)2013Angewandte Chemie (International ed. in English), Dec-23, Volume: 52, Issue:52
4-Acyl pyrroles: mimicking acetylated lysines in histone code reading.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (37)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (18.92)18.7374
1990's5 (13.51)18.2507
2000's9 (24.32)29.6817
2010's14 (37.84)24.3611
2020's2 (5.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 108.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index108.76 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index195.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (108.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.26%)6.00%
Case Studies1 (2.63%)4.05%
Observational0 (0.00%)0.25%
Other35 (92.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]